Literature DB >> 20062925

The clinical implications of new oral anticoagulants: will the potential advantages be achieved?

Katherine W Phillips1, Jack Ansell.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 20062925     DOI: 10.1160/TH09-06-0361

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  5 in total

Review 1.  [New oral anticoagulants: better than vitamin K antagonists?].

Authors:  H Völler; S Alban; D Westermann
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

Review 2.  New anticoagulants for the treatment of venous thromboembolism.

Authors:  Caio Julio Cesar Dos Santos Fernandes; José Leonidas Alves Júnior; Francisca Gavilanes; Luis Felipe Prada; Luciana Kato Morinaga; Rogerio Souza
Journal:  J Bras Pneumol       Date:  2016-04       Impact factor: 2.624

3.  Anticoagulation in Atrial Fibrillation.

Authors:  Yousif Ahmad; Gregory Yh Lip
Journal:  Arrhythm Electrophysiol Rev       Date:  2012-09

4.  Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs.

Authors:  Raul Altman; Claudio Daniel Gonzalez
Journal:  Thromb J       Date:  2014-03-21

Review 5.  New oral anticoagulants may be particularly useful for asian stroke patients.

Authors:  Oh Young Bang; Keun-Sik Hong; Ji Hoe Heo; Jaseong Koo; Sun U Kwon; Kyung-Ho Yu; Hee-Joon Bae; Byung-Chul Lee; Byung-Woo Yoon; Jong S Kim
Journal:  J Stroke       Date:  2014-05-30       Impact factor: 6.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.